DEF: Curis Proposes Reverse Stock Split to Maintain Nasdaq Listing

Curis, Inc. has scheduled a special meeting for June 25, 2026, to seek shareholder approval for a reverse stock split ranging from 1-for-5 to 1-for-25.

Summary

• The company is seeking shareholder approval to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25.
• The primary objective is to increase the per-share trading price to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
• The board of directors has the discretion to determine the final ratio and the timing of the implementation within six months of approval.
• The company received a delist determination letter from Nasdaq on April 27, 2026, due to the stock price closing below $1.00 for 30 consecutive business days.
• A virtual special meeting is scheduled for June 25, 2026, to vote on the reverse split and a potential adjournment proposal.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a defensive measure necessitated by poor stock performance and the threat of delisting, which typically signals underlying financial pressure.

Positives

• The reverse stock split is a strategic move to maintain Nasdaq listing, which helps preserve liquidity and institutional investor interest.
• The board has flexibility to choose the optimal ratio within the approved range to best meet listing requirements.
• The proposal includes a provision to round up fractional shares to the nearest whole share, avoiding cash-out scenarios for small holders.

Negatives

• The need for a reverse stock split indicates a significant decline in the company's share price and market valuation.
• A reverse split does not guarantee a permanent increase in share price and may be perceived negatively by the market.
• The action may result in higher transaction costs and reduced liquidity for shareholders.

Risks

• There is no assurance that the reverse stock split will result in a sustained share price above $1.00.
• The company faces the risk of delisting from Nasdaq if it fails to regain compliance with the bid price rule.
• Delisting could lead to reduced visibility, lower liquidity, and potential loss of confidence from partners and lenders.
• The market capitalization may decrease following the split due to factors unrelated to the corporate action.

Future Outlook

The company intends to use the reverse stock split to maintain its Nasdaq listing and improve marketability, though it acknowledges that future share price performance remains dependent on market conditions and business results.

Management Comments

• The board believes the reverse stock split is in the best interests of the company and its stockholders to meet Nasdaq listing criteria.
• Management aims to increase the share price to attract a broader range of institutional investors.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often last-resort, mechanism for small-cap biotechnology companies to avoid delisting from major exchanges when share prices fall into 'penny stock' territory.

Comparison to Industry Standards

• The use of a 1-for-5 to 1-for-25 range is consistent with standard practices for Nasdaq-listed companies seeking to regain compliance.
• The decision to hold a virtual-only meeting is increasingly standard for mid-to-small cap companies to reduce administrative costs and improve accessibility.

Corporate Governance

Stakeholder Impact

• Shareholders will see a reduction in the number of shares held, with a proportional increase in share price.
• Institutional investors may be more inclined to hold the stock if the price exceeds $1.00.
• Employees and creditors benefit from the company maintaining its Nasdaq listing status.

Next Steps

• Hold the virtual Special Meeting on June 25, 2026.
• Tabulate votes and report results via Form 8-K within four business days.
• If approved, the board will determine the final split ratio and file the amendment with the Delaware Secretary of State.

Key Dates

Recommendation

The filing indicates significant distress regarding the company's ability to maintain its Nasdaq listing. While the reverse split is a necessary technical step to avoid delisting, it does not address the fundamental business challenges that led to the share price decline. Investors should hold until there is evidence of operational improvement.

Keywords

Curis, CRIS, Reverse Stock Split, Nasdaq, Delisting, Proxy Statement, Biotech, Corporate Governance